Kanamycin Inj Rx
Generic Name and Formulations:
Kanamycin sulfate 500mg/vial, 1g/vial; soln for IM inj or IV infusion, intraperitoneal, nebulization, irrigation after dilution; contains sulfites.
Various generic manufacturers
Indications for Kanamycin Inj:
Short-term treatment of serious susceptible infections.
Adults and Children:
Obesity: base dose on lean body mass. IM: inject into upper outer quadrant of gluteal muscle. 15mg/kg/day in divided doses every 12 hours; or 15mg/kg/day in divided doses every 6–8 hours if continuously high blood levels desired. IV: infuse slowly over 30–60 mins; 15mg/kg/day in 2–3 divided doses. Usual duration: 7–10 days. Intraperitoneal, nebulization, irrigation: see literature. All routes: max 1.5g/day. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >35micrograms/mL and trough levels >10micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Monitor BUN, CrCl, serum creatinine levels before, frequently during, and after therapy. Perform audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism, or infant botulism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D), nursing mothers: not recommended.
Avoid concomitant furosemide, ethacrynic acid, mannitol. Diuretics may increase toxicity. Increased risk of neurotoxicity and/or nephrotoxicity with concurrent or sequential polymyxin B, colistin, amphotericin B, other nephrotoxic or neurotoxic drugs; avoid. May potentiate neuromuscular blockade, respiratory paralysis with anesthetics, neuromuscular blockers. May be antagonized by concomitant penicillins, cephalosporins.
Nephro- or ototoxicity, neurotoxicity, neuromuscular blockade (eg, muscular paralysis, apnea), local irritation or pain; rare: rash, drug fever, headache, GI upset, paresthesia.
Formerly known under the brand name Kantrex.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma